Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAmbetter Georgia definitive drug testing Coverage …
    Ask Trek AI about this page
    CurrentAmbetter GeorgiaPolicy CP.MP.50

    Drugs of Abuse: Definitive Testing

    Customize your policy alerts

    Sign up for Ambetter Georgia Policy CP.MP.50 alerts

    Get alerted when Policy CP.MP.50 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Rules for outpatient definitive/confirmatory drug testing (urine and other sources) including medical necessity criteria, limits on number of drug classes, and exclusions for administrative/screening uses that affect providers ordering and billing for Ambetter Georgia members.

    Policy Summary
    PayerAmbetter Georgia
    PolicyDrugs of Abuse: Definitive Testing
    Policy CodePolicy CP.MP.50
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review Date
    Key ActionObtain and document a presumptive/prescreen test result and clinical rationale before requesting definitive testing (except when no reliable presumptive test exists).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤ 14drugs/drug classes allowed for definitive testing when medically necessary
    14+considered not medically necessary for outpatient definitive testing
    children < 6testing exempt from prior authorization
    CPT/HCPCS listedprocedure codes referenced for coverage guidance

    Coverage Criteria for Definitive (Confirmatory) Drug Testing

    A. Documented history/suspicion with prior presumptive testing

    Covered when ALL of the following are met

    Group A: Documented history or suspicion of illicit or prescription drug use or noncompliance or a high probability of non-adherence to a prescribed drug regimen documented in the medical record

    and all of the following

    A1: A preliminary/presumptive drug test has been previously performed, unless no reliable test exists (e.g., synthetic cannabinoids)

    A2

    • A2a: Presumptive test findings are inconsistent with expected results based on medical history, clinical presentation, or the member's statement after detailed discussion
    • A2b: Presumptive test findings are consistent with the clinical scenario but drug class–specific assays are required to identify the precise drug(s)
    A3: Resolving the inconsistency is essential to the ongoing care of the member/enrollee
    A4: Requested confirmatory/definitive test(s) is for ≤ 14 drugs/drug classes<=14
    A5: Tests are limited to the specific drug(s) or number of drug classes for which the preliminary analysis yielded unexpected results

    B. Expected presumptive positive with need for quantitative levels

    Covered when ALL of the following are met

    Group B: The provider expects the presumptive test to be positive (e.g., the member/enrollee reports recent use)

    and all of the following

    B1: Information regarding the specific substance and/or quantity is desired
    B2: There are established benchmarks for clinical decision making based on specific substance and/or quantitative levels
    B3: ≤ 14 drugs/drug classes are requested<=14

    C. Therapeutic drug monitoring (serum)

    Covered when ANY of the following are met

    Group C: Request is for a serum therapeutic drug level in relation to medical treatment of a disease or condition (e.g., phenobarbital level for seizures)

    Not Medically Necessary / Exclusions

    Not medically necessary when ANY of the following apply

    NotCovered1: Testing as a condition of employment, pre-employment, or continuation of employment
    NotCovered2: Screening for school or community athletic or extracurricular participation
    NotCovered3: Screening for medico-legal purposes such as court-ordered drug screening (unless required by state regulations)
    NotCovered4: Screening in asymptomatic patients, except as listed in sections I or II
    NotCovered5: Component of routine physical or other administrative medical examinations (e.g., enrollment, marriage licensure, insurance eligibility)

    Urine drug testing and other definitive drug assays are not intended for routine administrative or screening-only uses. The policy expressly excludes testing performed as a condition of employment or pre‑employment, participation in school or community athletics or extracurricular activities, and screening for medico‑legal purposes (unless required by state regulation). Also excluded are screening of asymptomatic patients (except where the policy lists covered indications), testing as part of routine physicals or other administrative exams (for example, enrollment or insurance eligibility), blanket orders or routine standing orders for all patients, reflex definitive testing following point‑of‑care presumptive testing, and specimen validity/adulteration testing which is considered a laboratory quality control activity.

    Certain CPT/HCPCS codes are identified in this policy as not supporting the coverage criteria and therefore may be denied when billed. Examples called out in the policy include CPT codes 0054U, 0082U, and 0328U; these represent very large definitive panels and are listed under “CPT Codes That Do Not Support Coverage Criteria.”

    The policy lists several contexts that are specifically considered not medically necessary and not appropriate reasons for ordering definitive drug testing. These include testing required for employment or pre‑employment, screening for school or community athletic participation, court‑ordered or other medico‑legal screening (unless state regulations mandate it), asymptomatic population screening outside the policy’s covered indications, testing performed as part of routine physicals or other administrative exams, and blanket or standing orders that apply to all patients.

    Definitive assays billed as supporting medical necessity must meet required methodological quality standards. Tests performed without method‑ or drug‑specific calibration, without matrix‑matched quality control material, or without use of stable isotope or other universally recognized internal standards for each analyte are identified in the policy (see HCPCS G0659) as not meeting the policy’s methodological requirements and therefore do not support coverage criteria.

    When Definitive Testing Is Covered

    Definitive testing for drug identification and confirmation when performed using acceptable methodologies (GC/MS, LC/MS) with required internal standards and QC.

    Definitive Testing Method Requirements: Definitive testing performed using drug identification methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS, LC/MS), with stable isotope or other universally recognized internal standards, method/drug-specific calibration, and matrix-matched quality control material; qualitative or quantitative and includes specimen validity testing

    Coverage described per-day with drug-class count groupings (1-7; 8-14)

    Per-day drug class groupings: Coverage described using per-day billing and drug-class count groupings corresponding to HCPCS codes: 1-7 classes (G0480/G0481 first entry) and 8-14 classes (G0481 second entry)

    Limits on Number of Drug Classes per Request

    Number of drug classes per request
    Allowed maximum (outpatient definitive testing)≤ 14 drugs/drug classes per request
    Not medically necessary threshold> 14 drugs/drug classes considered not medically necessary for outpatient definitive testing
    Applicable policy sectionSee Policy I.A.4 and II for limits on number of drug classes
    Maximum drug classes for definitive testing
    Maximum drug classes14 drug classes
    ContextRequests for more than 14 drug classes are considered not medically necessary for outpatient definitive testing

    CPT / HCPCS Codes and Billing Guidance

    Covered CPT Codes (support coverage criteria)CPTCovered
    0011UPrescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites.
    80184Phenobarbital.
    80320Alcohols.
    80321Alcohol biomarkers; 1 or 2.
    80322Alcohol biomarkers; 3 or more.
    80323Alkaloids, not otherwise specified.
    80324Amphetamines; 1 or 2.
    80325Amphetamines; 3 or 4.
    80326Amphetamines; 5 or more.
    80327Anabolic steroids; 1 or 2.
    1–10 of 58
    1/6
    CPT Codes That Do Not Support Coverage CriteriaCPTNot Covered
    0054UPrescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges.
    0082UDrug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine.
    0328UDrug assay, definitive, 120 or more drugs and metabolites, urine, quantitative LC-MS/MS, includes specimen validity and algorithmic analysis.
    HCPCS Codes That Support Coverage CriteriaHCPCSCovered
    G0480Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers, including, but not limited to, GC/MS and LC/MS; stable isotope or other universally recognized internal standards in all samples; method/drug-specific calibration and matrix-matched quality control material; qualitative or quantitative, all sources, includes specimen validity testing, per day, 1 to 7 drug class(es), including metabolite(s) if performed.
    G0481Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers, including, but not limited to, GC/MS and LC/MS; stable isotope or other universally recognized internal standards in all samples; method/drug-specific calibration and matrix-matched quality control material; qualitative or quantitative, all sources, includes specimen validity testing, per day, 8 to 14 drug class(es), including metabolite(s) if performed.
    CPT Codes That Do Not Support Coverage CriteriaCPTNot Covered
    0054UPrescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges.
    0082UDrug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine.
    0328UDrug assay, definitive, 120 or more drugs and metabolites, urine, quantitative LC-MS/MS, includes specimen validity and algorithmic analysis.
    HCPCS Codes That Support Coverage CriteriaHCPCSCovered
    G0481Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers; includes specimen validity testing, per day, 1 to 7 drug class(es).
    G0481-8to14Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers; includes specimen validity testing, per day, 8 to 14 drug class(es).
    HCPCS Codes - performed without required QC/calibrationHCPCSNot Covered
    G0659Definitive testing performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s); qualitative or quantitative, any number of drug classes.
    HCPCS Codes That Do Not Support Coverage CriteriaHCPCSNot Covered
    G0482Drug test(s), definitive, utilizing acceptable definitive methods with required internal standards and QC; per day, 15 to 21 drug class(es).
    G0483Drug test(s), definitive, utilizing acceptable definitive methods with required internal standards and QC; per day, 22 or more drug class(es).
    NOT COVERED — Large-panel definitive tests
    Policy exclusion summaryLarge-panel definitive tests that enumerate very high numbers of drugs are listed as not supporting coverage criteria (examples: panels claiming 90 or 120+ drugs).
    Specific CPT codes not supported0054U — Prescription drug monitoring, 14 or more classes (definitive tandem MS with chromatography, capillary blood) and descriptions including therapeutic/toxic ranges; 0082U — Drug test(s), definitive, 90 or more drugs or substances (definitive chromatography with MS plus presumptive testing by instrument chemistry analyzer); 0328U — Drug assay, definitive, 120 or more drugs/metabolites, urine, quantitative LC-MS/MS, includes specimen validity and algorithmic analysis.
    Implication for billingClaims billed with these CPT codes (0054U, 0082U, 0328U) are considered to not support coverage criteria and may be denied under this policy.
    Relation to drug-class thresholdsThese large-panel CPT codes represent test offerings that exceed the policy's allowable outpatient definitive testing limit (see maximum of ≤14 drug classes); therefore they are excluded from coverage.

    Provider Documentation, Authorization, and Billing Actions

    Prior Authorization

    Prior authorization required for definitive testing

    Prior authorization is required per plan protocols for outpatient definitive/confirmatory drug testing. Exceptions and specific prior authorization protocols (see pediatric exemption below) apply.

    Prior Authorization

    Pediatric (<6 yrs) prior authorization exemption and timing

    Testing for children younger than 6 years of age is exempt from prior authorization. Per updated protocols, prior authorization requests for these pediatric cases will be accepted up to 10 business days after specimen collection and reviewed for medical necessity.

    • Exemption applies to children < 6 years of age.
    • Prior authorization requests for exempt pediatric tests may be submitted up to 10 business days after specimen collection.

    Requirements for Ordering Clinicians

    Note

    Ordering clinician must understand testing type, reasons, and limitations

    The ordering clinician must be knowledgeable about the type of testing requested, the clinical reason for testing, and the likelihood of false-positive or false-negative results; presumptive testing is generally expected before definitive testing unless no reliable presumptive test exists.

    • Document awareness of testing limitations and expected findings
    • Select tests based on likely exposure, metabolites of interest, and clinical question
    Prior Authorization

    Pediatric PA exemption and timing for PA submission

    Testing for children under six years of age is exempt from prior authorization; for exempt pediatric specimens, prior authorization requests may be accepted up to 10 business days after specimen collection for review.

    • Exempt from PA: children < 6 years
    • PA requests accepted up to 10 business days after collection for exempt pediatric cases

    Definitions

    Drug of abuse (DOA) — definition
    DefinitionA medication, substance, chemical, or plant product known to be misused for recreational or non-prescribed purposes
    Common screening targetsIncludes amphetamine, cocaine, marijuana, opioids, and phencyclidine among others
    Clinical relevanceDefinition used to frame when definitive testing for drugs of abuse (DOA) is appropriate
    Definitive/confirmatory testing — definition
    DefinitionAnalytical methods such as GC/MS or LC/MS used to specifically identify and/or quantify drugs or metabolites with high specificity
    Typical useThese methods are typically used as confirmatory/definitive tests rather than preliminary screening

    Background and Rationale

    Urine drug testing is used clinically to assist diagnosis, to monitor adherence to prescribed controlled substances, and to detect misuse. The policy differentiates between initial immunoassay‑based presumptive screens, which are commonly used at point of care but can yield false positives or negatives, and laboratory definitive methods (for example, GC/MS and LC‑MS/MS) that provide specific identification and/or quantification of drugs and metabolites. Definitive testing is reserved for situations such as resolving unexpected or inconsistent presumptive results, obtaining quantitative levels for clinical decision‑making, or measuring serum therapeutic drug levels tied to treatment.

    Not Covered / Exclusions

    Large‑panel definitive tests that report very high numbers of drugs (for example the wide panels described in the CPT entries cited in this policy) are listed under CPT Codes That Do Not Support Coverage Criteria and are not supported for coverage under this policy.

    As noted elsewhere in the policy, tests billed with CPT codes 0054U, 0082U, or 0328U, or HCPCS codes G0482 or G0483, are categorized as not supporting the coverage criteria and therefore may be denied.

    The policy states that definitive testing performed without essential methodologic safeguards—specifically without method‑ or drug‑specific calibration, without matrix‑matched quality control materials, or without use of stable isotope or other universally recognized internal standards for each analyte—does not support coverage and is identified in the policy as not covered (see HCPCS G0659).

    Policy Revision History

    2026-08-01policy_effective_dateLatest

    Policy CP.MP.50 became effective (Clinical Policy: Drugs of Abuse: Definitive Testing).

    03/26/2026annual_review

    Annual review: coding and descriptions reviewed; references reviewed and updated (annual review entry recorded 03/26).

    03/25/2025annual_review
    Policy Summary
    PayerAmbetter Georgia
    PolicyDrugs of Abuse: Definitive Testing
    Policy CodePolicy CP.MP.50
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review Date
    Key ActionObtain and document a presumptive/prescreen test result and clinical rationale before requesting definitive testing (except when no reliable presumptive test exists).
    SourceLink
    On This Page
    Coverage Criteria for Definitive (Confirmatory) Drug TestingWhen Definitive Testing Is CoveredLimits on Number of Drug Classes per RequestCPT / HCPCS Codes and Billing GuidanceProvider Documentation, Authorization, and Billing ActionsRequirements for Ordering CliniciansDefinitionsBackground and RationaleNot Covered / ExclusionsPolicy Revision History
    B4: Tests are limited to the specific drug(s) or number of drug classes for which the presumptive test is expected to be positive
    NotCovered6: Same-day screening of drug metabolites from any combination of blood, saliva and urine by either preliminary or confirmatory analyses
    NotCovered7: Blanket orders or reflex definitive drug tests when presumptive testing is performed at point of care
    NotCovered8: Routine standing orders for all patients in a physician's practice (limited physician-defined standing orders for specific profiles may be reasonable and must be documented)
    NotCovered9: Billing of individual definitive CPT codes when a comprehensive definitive drug testing panel (CDDP) is ordered
    NotCovered10: Performing presumptive point of care testing and ordering presumptive immunoassay testing from a reference laboratory, with or without reflex testing
    NotCovered11: Specimen validity/adulteration testing, as this is considered part of laboratory quality control and not separately covered
    Policy reference
    Frequency limits and Policy II state the 14-class maximum
    Drug class count thresholds
    G0481 (first entry)1–7 drug class(es) per day
    G0481 (second entry)8–14 drug class(es) per day
    G048215–21 drug class(es) per day (does not support coverage criteria)
    G048322 or more drug class(es) per day (does not support coverage criteria)
    Action for providersOrder definitive testing using codes and panels that align with policy thresholds (e.g., per-day drug-class groupings supported by HCPCS G0480/G0481 or CPT codes within covered range) rather than the listed large-panel CPTs to avoid denial.

    Tests billed with CPT codes 0054U, 0082U, or 0328U and HCPCS codes G0482 or G0483 are listed in this policy as not supporting the coverage criteria and therefore may be denied when submitted for outpatient definitive drug testing. CPT 0054U, 0082U, and 0328U describe very large-panel definitive assays (e.g., 14 or more classes, 90 or more drugs, 120 or more drugs/metabolites) that the policy explicitly places in the “CPT Codes That Do Not Support Coverage Criteria” group. HCPCS codes G0482 and G0483 correspond to per-day definitive testing for 15–21 and 22 or more drug class(es), respectively, and are likewise listed as not supporting the coverage criteria.

    Definitive assays performed without method- or drug-specific calibration, without matrix-matched quality control material, or without the use of stable isotope or other universally recognized internal standard(s) for each drug/drug class are identified in this policy as unsupported for coverage. The policy describes HCPCS code G0659 for definitive testing performed without these required calibration/quality-control elements and indicates such tests do not meet the methodologic standards required for coverage.

    Step Therapy

    Presumptive test expected before definitive testing

    A presumptive (qualitative) test is generally expected before ordering definitive/confirmatory testing unless no reliable presumptive test exists (for example, synthetic cannabinoids) or the clinician documents expectation of a positive presumptive result and a need for quantitative information.

    • Perform and document a preliminary/presumptive test prior to definitive testing when reliable presumptive methods exist.
    • If no reliable presumptive test exists (e.g., synthetic cannabinoids), definitive testing may be requested without prior presumptive testing.
    Documentation Required

    Ordering clinician documentation and knowledge requirement

    Follow ordering and documentation requirements described in the policy: the ordering clinician must be knowledgeable about the test type, reason for testing, and likelihood of false positives/negatives; include these details when ordering definitive testing.

    • Document the type of testing requested and the clinical reason for the test.
    • Ordering clinician should demonstrate awareness of potential false positives/negatives and the expected findings.
    Documentation Required

    Medical record must document history/suspicion and rationale

    Document in the medical record the history or clinical suspicion of illicit or prescription drug use or noncompliance and the clinical rationale showing why resolving inconsistent or unexpected presumptive results is essential to ongoing care.

    • Record member history, clinical presentation, and discussion about recent medication/drug use.
    • State why resolving inconsistent presumptive results is necessary for the member's care.
    Documentation Required

    Methodologic documentation required for definitive testing

    When requesting definitive testing, document the laboratory methodology and quality controls: tests must use methods able to identify individual drugs and distinguish structural isomers, include stable isotope or other universally recognized internal standards, and employ method/drug-specific calibration with matrix-matched quality control material.

    • Specify the analytic method (e.g., GC/MS or LC/MS) capable of identifying individual drugs and distinguishing structural isomers.
    • Provide documentation of stable isotope or universally recognized internal standards in samples.
    • Include method/drug-specific calibration and matrix-matched quality control material in documentation.
    Denial Risk

    Requests >14 drug classes may be denied

    Outpatient definitive/confirmatory testing requests that include more than 14 drugs or drug classes are considered not medically necessary and may be denied.

    • Limit definitive testing orders to ≤ 14 drugs/drug classes for outpatient requests.
    Billing Rule

    Unsupported CPT/HCPCS codes may trigger denial

    Use of CPT or HCPCS codes listed in the policy as not supporting coverage criteria (for example CPT 0054U, 0082U, 0328U and HCPCS G0482, G0483) indicates the billed test does not meet coverage criteria and may trigger denial.

    • Do not bill definitive testing under CPT codes 0054U, 0082U, or 0328U when seeking coverage per this policy.
    • Do not bill under HCPCS codes G0482 or G0483 for outpatient definitive testing expecting coverage under these criteria.
    Laboratory requirementsRequire specialized training and instrumentation; include method/drug-specific calibration and QC per policy
    Definitive testing — definition
    DefinitionDefinitive testing: drug identification methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS, LC/MS)
    IncludesQualitative or quantitative assays and specimen validity testing when performed with required internal standards and matrix-matched QC
    Policy requirementDefinitive testing must use stable isotope or universally recognized internal standards and method/drug-specific calibration
    Non-supported definitive testing — definition
    DefinitionNon-supported definitive testing: assays performed without method- or drug-specific calibration, without matrix-matched quality control, or without use of stable isotope or other universally recognized internal standards
    Associated codeHCPCS G0659 describes definitive testing performed without required calibration/QC/standards and is not supported
    Coverage implicationDefinitive testing billed under these conditions is not supported by coverage criteria and may be denied

    Annual review with coding and description updates; references reviewed and updated; external specialist review noted.

    03/24/2024annual_review

    Annual review: policy statements updated to include 'Centene Advanced Behavioral Health'; background updated; references reviewed and updated; internal specialist review.

    12/22/2022protocol_update

    Prior authorization protocols added: testing for children < 6 years exempt from prior authorization and prior authorization accepted up to 10 business days after specimen collection.

    06/23/2023coding_update

    Removed deleted CPT codes (0143U–0150U) from the list of CPT codes that do not support coverage; coding table revised.

    03/22/2022annual_review

    Annual review: references reviewed and updated; background updated with no impact to criteria; description updated for CPT code 80370; specialist review.